• Catapult Receives FDA Clearance of IND for Humanized Anti-CCR7 Antibody americanpharmaceuticalreview
    February 22, 2021
    Catapult Therapeutics has announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its lead product candidate CAP-100, an innovative first-in-class humanized anti-CCR7 antibody for treatment ...
PharmaSources Customer Service